PharmaNest, a leader in high resolution quantitative Digital Pathology and Artificial Intelligence, announces today the launch new quantitative tissue panels to properly quantify tissue injury and inflammation in the context of multiple fibrotic conditions, from discovery models to clinical development. Such spatially resolved datasets can be fused with other spatially resolved biology methods.

PharmaNest, a leader in high resolution, single-fiber, quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest Ph-FCS continuous fibrosis biomarker for the quantification of the severity of fibrosis and prognostics of liver related clinical events in NASH.

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous scores for the quantification of the treatment effects of NASH therapies at the 2022 Liver Meeting® | AASLD conference

Spanish-Language Website Launched

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) enter a strategic partnership to use artificial intelligence (AI) powered tool for the diagnosis and staging of NASH (non-Alcoholic Steatohepatitis) in patients with type 2 diabetes (T2D).

New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021

Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and regression of Fibrosis in human in-vitro 3D NASH Spheroid models and for the automated classification of post-transplant patients in F4 Fibrosis Stage with and without Hepatocellular carcinoma (HCC) at the Liver Meeting Digital Experience 2020

New digital image analysis data of stained tissues and biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in pre-clinical tissues and adult NASH biopsies at the Digital International Liver CongressTM 2020

New image analysis data of biopsies with FibroNest is presented for the continuous assessment of the severity and progression of fibrosis in NASH in both adult and pediatric cohorts at the Liver Meeting® 2019.

FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects.

Results Demonstrate that GEN-3026 Successfully Met the Primary Study Endpoint of Treating and Preventing Progression of NASH

The recession forced Mark Nash to reconsider his compensation options. With a slowing real estate market, Nash a long-time Chicago broker decided that his interest in art might be propagated in his extra free time.